Role of race in oncogenic driver prevalence and outcomes in lung adenocarcinoma: Results from the Lung Cancer Mutation Consortium
Conor Steuer(Emory University), Suresh S. Ramalingam(Emory University), Gabriel Sica(Emory University), Lynne D. Berry(Vanderbilt University Medical Center), Mark G. Kris(Memorial Sloan Kettering Cancer Center), Michael R. Rossi(Sema4 (United States)), Bruce E. Johnson(Harvard University), Fadlo R. Khuri(American University of Beirut Medical Center), Edward B. Garon(University of California, Los Angeles), Paul A. Bunn(University of Colorado Denver), Madhusmita Behera(National Institutes of Health), Sungjin Kim(Cedars-Sinai Medical Center), Taofeek K. Owonikoko(UPMC Hillman Cancer Center)
Cited by 118
Related Papers
<i>EGFR</i> Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
|Science|2004|9.4k
<i>MET</i> Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
|Science|2007|4.5k
Osimertinib or Platinum–Pemetrexed in <i>EGFR</i> T790M–Positive Lung Cancer
|New England Journal of Medicine|2016|3.3k
Genomic Classification of Cutaneous Melanoma
|Cell|2015|3.3k